Pharma Marketing Network

OCTOBER 24, 2024

New drugs, evolving technologies, and emerging marketing channels are creating fresh opportunities for pharma marketing executives. As more patients turn to digital platforms for information and brands compete in an increasingly crowded market, pharma marketers need to be agile, creative, and tech-savvy to succeed.

Marketing 52

Marketing Branding Pharma Companies Compliance 52

Pharma Mirror

JANUARY 5, 2024

New Delhi, India – FD-AID, LLC, a distinguished leader in pharmaceutical quality and compliance solutions, proudly announces its entry into the Indian pharmaceutical market.

Compliance 130

Compliance FDA Compliance Marketing Drugs 130

Intouch Solutions

NOVEMBER 18, 2021

Let’s talk about what that means for pharma marketers! Why Pharma Marketers Should Care About RSAs RSAs are a text ad format that requires an increased number of headline and description line variations than ETAs require. Among the concerns that pharma marketers face: The RSA ad format will be new to most MLR reviewers.

Branding 52

Branding FDA Compliance Marketing Regulation 52

FDA Law Blog

JANUARY 1, 2024

The FDA compliance data, sorted by category, shows there were 159 Warning Letters issued to drug manufacturers or sponsors during 2023, with 161 issued in calendar year 2022. FDA stated that the firm received 96 U.S. Summaries of the most striking recently released Warning Letters are included below. Dextrum Laboratories Inc.

Manufacturing 57

Manufacturing Production Drugs Contract Manufacturing 57

Cloudbyz

AUGUST 19, 2024

Manufacturers must adhere to a wide array of standards and guidelines that dictate how devices are developed, tested, and brought to market. Compliance with their regulations is mandatory for manufacturers seeking to market their devices globally. What is the role of post-market surveillance in medical device safety?

Compliance 52

Compliance Manufacturing Regulation Marketing 52

FDA Law Blog

JUNE 9, 2021

Koblitz — While typically, FDA is responsible for setting forth its own agenda and enforcing compliance with its own regulations, the Trump Administration’s HHS, on its way out the door in late 2020 , took the unusual steps of withdrawing an important FDA Compliance Policy Guide, “Marketed Unapproved Drugs – Compliance Policy Guide Sec.

Compliance 52

Compliance Drugs Production Marketing 52